Статья
Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского Кардиологического Общества, Российского Общества Акушеров-Гинекологов, Российской Ассоциации Эндокринологов, Евразийской Ассоциации Терапевтов, Ассоциации Флебологов России
Климактерические симптомы могут нарушать ход жизни женщин на пике карьеры и семейной жизни. В настоящее время самым эффективным методом лечения этих проявлений является менопаузальная гормональная терапия (МГТ). Наличие сердечно-сосудистых и метаболических заболеваний само по себе не исключает возможность назначения МГТ с целью купирования климактерических симптомов и улучшения качества жизни. Однако нередко препятствием для использования этого вида гормональной терапии являются опасения врачей, которые боятся принести пациенткам больше вреда, чем пользы. Осторожность особенно важна, когда речь идет о женщинах, страдающих сопутствующими заболеваниями. Более того, следует признать, что качественных исследований относительно безопасности МГТ при основных хронических неинфекционных заболеваниях и часто встречаемых коморбидных состояниях недостаточно. В представленном согласительном документе проведен анализ всех доступных в настоящее время данных, полученных в ходе клинических исследований различного дизайна, и создан свод критериев приемлемости назначения МГТ женщинам с сопутствующими сердечно-сосудистыми и метаболическими заболеваниями. Опираясь на представленный документ, врачи различных специальностей, консультирующие женщин в климактерии, получат доступный алгоритм, позволящий избегать потенциально опасных ситуаций и обоснованно назначать МГТ в реальной практике.
1. Распоряжение Правительства РФ от 29 дек. 2022 г. № 4356-р «Об утверждении Национальной стратегии действий в интересах женщин на 2023 - 2030 годы». Доступно на: https://www.consultant.ru/document/cons_doc_LAW_436691
2. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения, обучения. Вестник ВШОУЗ. 2020;6(4(22)):23-53. DOI: 10.24411/2411-8621-2020-14002
3. Lambrinoudaki I, Armeni E, Goulis D, Bretz S, Ceausu I, Durmusoglu F et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1-14. DOI: 10.1016/j.maturitas.2022.04.008
4. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2021. Доступно на: https://cr.minzdrav.gov.ru/recomend/117_2
5. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. DOI: 10.1097/gme.0b013e31824d8f40
6. Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus. 2015;4(1):65. DOI: 10.1186/s40064-015-0808-y
7. Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, O’Sullivan DM. The North American Menopause Society: from abstract to publication. Menopause. 2008;15(5):996-1001. DOI: 10.1097/gme.0b013e318166f026
8. Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Crawford SL et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017;24(2):142-9. DOI: 10.1097/GME.0000000000000736
9. Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., и др. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. 2015. Доступно на: https://www.consultant.ru/document/cons_doc_LAW_320073/
10. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. International Journal of Epidemiology. 2014;43(5):1542-62. DOI: 10.1093/ije/dyu094
11. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-32. DOI: 10.1097/GME.0000000000000196
12. Costanian C, Zangiabadi S, Bahous SA, Deonandan R, Tamim H. Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors. Climacteric. 2020;23(3):213-23. DOI: 10.1080/13697137.2019.1711051
13. Prior JC. Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts, Views & Vision in ObGyn. 2011;3(2):109-20. PMID: 24753856
14. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinology and Metabolism Clinics of North America. 2015;44(3):497-515. DOI: 10.1016/j.ecl.2015.05.001
15. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева ЛИ., Бирюкова Е.В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017;63(6):392-426. DOI: 10.14341/probl2017636392-426
16. Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R et al. Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(6):e0157417. DOI: 10.1371/journal.pone.0157417
17. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. DOI: 10.3109/13697137.2015.1129166
18. Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;148:55-61. DOI: 10.1016/j.maturitas.2021.04.005
19. Grundy SM. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. The Journal of Clinical Endocrinology & Metabolism. 2007;92(2):399-404. DOI: 10.1210/jc.2006-0513
20. Hu G, The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608-17. DOI: 10.1007/s00125-003-1096-6
21. Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T et al. Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project. PLoS ONE. 2014;9(9):e107294. DOI: 10.1371/journal.pone.0107294
22. Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):5-232. DOI: 10.15829/1728-8800- 2022-3235
23. Cushman M. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2004;292(13):1573-80. DOI: 10.1001/jama.292.13.1573
24. Трошина Е.А., Покусаева В.Н., Андреева Е.Н., Григорян О.Р., Мазурина Н.В., Дзгоева Ф.Х. и др. Ожирение у женщин. [Григорян О.Р., Андреева Е.Н. Ожирение и менопауза. С.233-268].- М.: Медицинское информационное агентство, 2017. - 272c. ISBN 978-5-9986-0296-2
25. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V et al. Antiadipogenic Effects of the Mineralocorticoid Receptor Antagonist Drospirenone: Potential Implications for the Treatment of Metabolic Syndrome. Endocrinology. 2011;152(1):113-25. DOI: 10.1210/en.2010-0674
26. Rizzo MR, Leo S, De Franciscis P, Colacurci N, Paolisso G. Shortterm effects of low-dose estrogen/drospirenone vs low-dose estrogen/ dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. AGE. 2014;36(1):265-74. DOI: 10.1007/s11357-013-9554-7
27. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204-21. DOI: 10.14341/DM12759
28. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials. JAMA. 2013;310(13):1353-68. DOI: 10.1001/jama.2013.278040
29. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism. 2006;8(5):538-54. DOI: 10.1111/j.1463-1326.2005.00545.x
30. Grigoryan O.R. Climacteric syndrome in women with diabetes mellitus. Diabetes Mellitus. 2013;16(3):103-8. DOI: 10.14341/2072-0351-824
31. Mendoza N, Ramírez I, De La Viuda E, Coronado P, Baquedano L, Llaneza P et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65-85. DOI: 10.1016/j.maturitas.2022.08.008
32. Kim J-E, Chang J-H, Jeong M-J, Choi J, Park J, Baek C et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Scientific Reports. 2020;10(1):20631. DOI: 10.1038/s41598-020-77534-9
33. Boardman HM, Hartley L, Eisinga A, Main C, Roqué I Figuls M, Bonfill Cosp X et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015;2015(8):CD002229. DOI: 10.1002/14651858. CD002229.pub4
34. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. DOI: 10.1136/bmj.k4810
35. Goldštajn MŠ, Mikuš M, Ferrari FA, Bosco M, Uccella S, Noventa M et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2022;307(6):1727-45. DOI: 10.1007/s00404-022-06647-5
36. Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(6):101578. DOI: 10.1016/j.beem.2021.101578
37. Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reproductive Health. 2023;29(1):33-41. DOI: 10.1177/20533691221148036
38. Blondon M, Timmons AK, Baraff AJ, Floyd JS, Harrington LB, Korpak AM et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans. Menopause. 2021;28(10):1125-9. DOI: 10.1097/GME.0000000000001823
39. Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022;29(4):483-90. DOI: 10.1097/GME.0000000000001938
40. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-94. DOI: 10.1097/GME.0000000000002028
41. Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349-56. DOI: 10.1080/13697137.2016.1183624
42. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678-700. DOI: 10.1016/j.contraception.2016.04.014
43. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. DOI: 10.1136/bmj.e4944
44. Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. IJC Heart & Vasculature. 2019;22:123-31. DOI: 10.1016/j.ijcha.2019.01.001
45. Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147(7):597-610. DOI: 10.1161/CIRCULATIONAHA.122.061559
46. LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Research and Practice in Thrombosis and Haemostasis. 2022;6(6):e12763. DOI: 10.1002/rth2.12763
47. Roach REJ, Lijfering WM, Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR, Cannegieter SC. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264-9. DOI: 10.1182/blood-2013-07-518159
48. Douketis JD, Julian JA, Crowther MA, Kearon C, Bates SM, Barone M et al. The Effect of Prothrombotic Blood Abnormalities on Risk of Deep Vein Thrombosis in Users of Hormone Replacement Therapy: A Prospective Case-Control Study. Clinical and Applied Thrombosis/Hemostasis. 2011;17(6):E106-13. DOI: 10.1177/1076029610387587
49. Straczek C, Oger E, Yon De Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G et al. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration. Circulation. 2005;112(22):3495-500. DOI: 10.1161/CIRCULATIONAHA.105.565556
50. Bezemer ID, Van Der Meer FJM, Eikenboom JCJ, Rosendaal FR, Doggen CJM. The Value of Family History as a Risk Indicator for Venous Thrombosis. Archives of Internal Medicine. 2009;169(6):610-5. DOI: 10.1001/archinternmed.2008.589
51. Brighouse D. Hormone replacement therapy (HRT) and anaesthesia. British Journal of Anaesthesia. 2001;86(5):709-16. DOI: 10.1093/bja/86.5.709
52. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13. DOI: 10.1001/jama.280.7.605
53. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A et al. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women’s Health Initiative: A Randomized Trial. JAMA. 2003;289(20):2673-84. DOI: 10.1001/jama.289.20.2673
54. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE et al. Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425-34. DOI: 10.1161/CIRCULATIONAHA.105.594077
55. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. DOI: 10.1097/GME.0000000000001609
56. Te West NID, Day RO, Hiley B, White C, Wright M, Moore KH. Estriol serum levels in new and chronic users of vaginal estriol cream: A prospective observational study. Neurourology and Urodynamics. 2020;39(4):1137-44. DOI: 10.1002/nau.24331
57. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361- 70. DOI: 10.1097/GME.0000000000001463
58. Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2019;26(6):603-10. DOI: 10.1097/GME.0000000000001284
59. Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womens Health Initiative Observational Study. Menopause. 2018;25(1):11-20. DOI: 10.1097/GME.0000000000000956
60. Орлова Я.А., Плисюк А.Г., Долгушин Г.О., Кириллова К.И., Михеев Р.К., Андреева Е.Н. Связь длительной менопаузальной гормональной терапии и показателей сосудистого и репликативного старения у женщин. Профилактическая медицина. 2023;26(7):96- 102. DOI: 10.17116/profmed20232607196
61. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research. 2009;11(6):835-42. DOI: 10.1002/jbmr.5650110615
62. Nie G, Yang X, Wang Y, Liang W, Li X, Luo Q et al. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022;13:850815. DOI: 10.3389/fphar.2022.850815
63. Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):250-97. DOI: 10.15829/1560-4071-2023-5471
64. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal. 2010;31(23):2844-53. DOI: 10.1093/eurheartj/ehq386
65. Van Dam-Nolen DHK, Van Dijk AC, Crombag GAJC, Lucci C, Kooi ME, Hendrikse J et al. Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study. Atherosclerosis. 2021;329:22-9. DOI: 10.1016/j.atherosclerosis.2021.06.004
66. Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. The Journal of Clinical Endocrinology & Metabolism. 2015;100(6):2329-38. DOI: 10.1210/jc.2014-2649
67. Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208. DOI: 10.1001/jama.1995.03520270033028
68. Binder EF, Birge SJ, Kohrt WM. Effects of Endurance Exercise and Hormone Replacement Therapy on Serum Lipids in Older Women. Journal of the American Geriatrics Society. 1996;44(3):231-6. DOI: 10.1111/j.1532-5415.1996.tb00907.x
69. Bunyavejchevin S, Limpaphayom KK. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a doubleblind placebo-controlled trial. Journal of the Medical Association of Thailand. 2001;84(1):45-53. PMID: 11281499
70. Çayan F, Gen R, Akbay E, Dilek U, Dilek S. The Effect of Hormone Therapy and Tibolone on Glucose and Lipid Metabolism in Healthy Postmenopausal Women. Turkish Journal of Geriatrics. 2011;14(1):19-25. [Av. at: https://geriatri.dergisi.org/abstract.php?id=534]
71. Cheng GJ, Liu JL, Zhang Q, Fan W, Ye HF, Wang ZQ et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. Chinese Medical Journal. 1993;106(12):911-6. PMID: 8198628
72. Conard J, Basdevant A, Thomas J-L, Ochsenbein E, Denis C, Guyene TT et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertility and Sterility. 1995;64(5):957-62. DOI: 10.1016/S0015-0282(16)57909-6
73. Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertility and Sterility. 1997;68(3):449-53. DOI: 10.1016/S0015-0282(97)00220-3
74. Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N et al. Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Women. Archives of Internal Medicine. 2000;160(21):3315-25. DOI: 10.1001/archinte.160.21.3315
75. Duvernoy CS, Rose PA, Kim HM, Kehrer C, Brook RD. Combined Continuous Ethinyl Estradiol/Norethindrone Acetate Does Not Improve Forearm Blood Flow in Postmenopausal Women at Risk for Cardiovascular Events: A Pilot Study. Journal of Women’s Health. 2007;16(7):963-70. DOI: 10.1089/jwh.2006.0321
76. Casanova G, Dos Reis AM, Spritzer PM. Low-dose oral or nonoral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015;18(1):86-93. DOI: 10.3109/13697137.2014.940309
77. Haase CL, Tybjærg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. The Journal of Clinical Endocrinology & Metabolism. 2012;97(2):E248-56. DOI: 10.1210/jc.2011-1846
78. Lv C, Zhang W, Tan X, Shang X, Găman M-A, Salem H et al. The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacological Research. 2021;169:105612. DOI: 10.1016/j.phrs.2021.105612
79. Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2017;99:27-36. DOI: 10.1016/j.maturitas.2017.02.009
80. Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. British Journal of Obstetrics and Gynaecology. 1992;99(10):821-8. DOI: 10.1111/j.1471-0528.1992.tb14414.x
81. Shufelt CL, Manson JE. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. The Journal of Clinical Endocrinology & Metabolism. 2021;106(5):1245-54. DOI: 10.1210/clinem/dgab042
82. Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82-8. DOI: 10.1016/j.maturitas.2020.03.007
83. Wenger NK, Lloyd-Jones DM, Elkind MSV, Fonarow GC, Warner JJ, Alger HM et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2022;145(23):e1059-71. DOI: 10.1161/CIR.0000000000001071
84. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet. 2021;397(10292):2385-438. DOI: 10.1016/S0140-6736(21)00684-X
85. Reckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;27:176-81. DOI: 10.1097/MNH.0000000000000404
86. Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology. 2020;75(20):2602-18. DOI: 10.1016/j.jacc.2020.03.060
87. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C et al. Sex differences in arterial hypertension. European Heart Journal. 2022;43(46):4777-88. DOI: 10.1093/eurheartj/ehac470
88. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957-80. DOI: 10.1016/S0140-6736(21)01330-1
89. O’Keeffe LM, Simpkin AJ, Tilling K, Anderson EL, Hughes AD, Lawlor DA et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis. 2018;278:190-6. DOI: 10.1016/j.atherosclerosis.2018.09.030
90. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiology. 2020;5(3):19-26. DOI: 10.1001/jamacardio.2019.5306
91. Maas A, Rosano G, Cifkova R, Chieffo A, Van Dijken D, Hamoda H et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal. 2021;42(10):967-84. DOI: 10.1093/eurheartj/ehaa1044
92. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-32. DOI: 10.1161/CIR.0000000000000912
93. Biglia N, Cagnacci A, Gambacciani M, Lello S, Maffei S, Nappi RE. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306-12. DOI: 10.1080/13697137.2017.1315089
94. Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, TwumasiAnkrah B et al. Arterial Hypertension in Women: State of the Art and Knowledge Gaps. Hypertension. 2023;80(6):1140-9. DOI: 10.1161/HYPERTENSIONAHA.122.20448
95. Coutinho T. Arterial Stiffness and Its Clinical Implications in Women. Canadian Journal of Cardiology. 2014;30(7):756-64. DOI: 10.1016/j.cjca.2014.03.020
96. Picone DS, Kodithuwakku V, Mayer CC, Chapman N, Rehman S, Climie RE. Sex differences in pressure and flow waveform physiology across the life course. Journal of Hypertension. 2022;40(12):2373-84. DOI: 10.1097/HJH.0000000000003283
97. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, LloydJones DM et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women-2011 Update: A Guideline From the American Heart Association. Circulation. 2011;123(11):1243-62. DOI: 10.1161/CIR.0b013e31820faaf8
98. Issa Z, Seely EW, Rahme M, El-Hajj Fuleihan G. Effects of hormone therapy on blood pressure. Menopause. 2015;22(4):456-68. DOI: 10.1097/GME.0000000000000322
99. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. 2023; [Epub ahead of print]. DOI: 10.1097/HJH.0000000000003480
100. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218. DOI: 10.15829/1560-4071-2020-3-3786
101. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Archives of Internal Medicine. 2006;166(7):772- 80. DOI: 10.1001/archinte.166.7.772
102. Blondon M, Wiggins KL, Van Hylckama Vlieg A, McKnight B, Psaty BM, Rice KM et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population‐based, case-control study. British Journal of Haematology. 2013;163(3):418-20. DOI: 10.1111/bjh.12508
103. Li Y, Zhao D, Wang M, Sun J, Liu J, Qi Y et al. Association of menopause with risk of carotid artery atherosclerosis. Maturitas. 2021;143:171-7. DOI: 10.1016/j.maturitas.2020.10.007
104. Schreinlechner M, Noflatscher M, Reinstadler SJ, Sommer P, Lener D, Reiser E et al. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020;297:25-31. DOI: 10.1016/j.atherosclerosis.2020.01.023
105. Westendorp I, In’T Veld BA, Grobbee DE, Pols H, Meijer WT, Hofman A et al. Hormone Replacement Therapy and Peripheral Arterial Disease: The Rotterdam Study. Archives of Internal Medicine. 2000;160(16):2498-502. DOI: 10.1001/archinte.160.16.2498
106. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288(1):49-57. DOI: 10.1001/jama.288.1.49
107. Rockman CB, Maldonado TS, Jacobowitz GR, Adelman MA, Riles TS. Hormone Replacement Therapy is Associated With a Decreased Prevalence of Peripheral Arterial Disease in Postmenopausal Women. Annals of Vascular Surgery. 2012;26(3):411-8. DOI: 10.1016/j.avsg.2011.10.012
108. Davies RSM, Vohra RK, Bradbury AW, Adam DJ. The Impact of Hormone Replacement Therapy on the Pathophysiology of Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery. 2007;34(5):569-75. DOI: 10.1016/j.ejvs.2007.06.002
109. Поляков Д.C., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА -ХСН. Кардиология. 2021;61(4):4-14. DOI: 10.18087/cardio.2021.4.n1628
110. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360. DOI: 10.1161/CIR.0000000000000350
111. Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta‐Analysis. Journal of the American Heart Association. 2016;5(8):e003769. DOI: 10.1161/JAHA.116.003769
112. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. DOI: 10.1136/bmj.e6409
113. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, Khan S, Adams K, Goldman S et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology. 2003;42(7):1238-45. DOI: 10.1016/S0735-1097(03)00938-0
114. Liu L, Klein L, Eaton C, Panjrath G, Martin LW, Chae CU et al. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women’s Health Initiative Randomized Trials. Journal of Cardiac Failure. 2020;26(1):2-12. DOI: 10.1016/j.cardfail.2019.09.006
115. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-962. DOI: 10.1093/eurheartj/ehw210
116. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation. 2005;112(12):1687- 91. DOI: 10.1161/CIRCULATIONAHA.105.553438
117. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Lévy S, Cobbe S et al. Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. Journal of the American College of Cardiology. 2007;49(5):572-7. DOI: 10.1016/j.jacc.2006.10.047
118. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa T et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. EP Europace. 2018;20(10):1565-1565ao. DOI: 10.1093/europace/euy067
119. Thompson LE, Maddox TM, Lei L, Grunwald GK, Bradley SM, Peterson PN et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. Journal of the American Heart Association. 2017;6(7):e005801. DOI: 10.1161/JAHA.117.005801
120. Lee J, Kim Y, Park H, Kim C, Cho S, Kim J. Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. Journal of Clinical Medicine. 2021;10(23):5497. DOI: 10.3390/jcm10235497
121. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588-97. DOI: 10.1161/CIRCULATIONAHA.117.028981
122. Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD et al. Effects of Postmenopausal Hormone Therapy on Incident Atrial Fibrillation: The Women’s Health Initiative Randomized Controlled Trials. Circulation: Arrhythmia and Electrophysiology. 2012;5(6):1108- 16. DOI: 10.1161/CIRCEP.112.972224
123. Tsai W-C, Haung Y-B, Kuo H-F, Tang W-H, Hsu P-C, Su H-M et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Scientific Reports. 2016;6(1):24132. DOI: 10.1038/srep24132
124. Wong JA, Rexrode KM, Sandhu RK, Moorthy MV, Conen D, Albert CM. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017;103(24):1954-61. DOI: 10.1136/heartjnl-2016-311002
125. Fleury M-A, Clavel M-A. Sex and Race Differences in the Pathophysio - logy, Diagnosis, Treatment, and Outcomes of Valvular Heart Diseases. Canadian Journal of Cardiology. 2021;37(7):980-91. DOI: 10.1016/j.cjca.2021.02.003